Workload, Recurrence, Quality of Life and Long-term Efficacy of Endoscopic Therapy for High-grade Dysplasia and Intramucosal Esophageal Adenocarcinoma.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
25
9
2018
medline:
5
6
2020
entrez:
25
9
2018
Statut:
ppublish
Résumé
To review the workload, type and frequency of recurrence, long-term quality of life (QOL), and late oncologic outcomes with endoscopic therapy. The short-term oncologic efficacy of endoscopic resection (ER) and ablation for patients with high-grade dysplasia (HGD) or intramucosal adenocarcinoma (IMC) is well-established in the literature. A retrospective chart review was performed of the initial 40 patients who had endoscopic therapy from 2001 to 2010 at 1 center by 1 physician. Initial pathology was HGD in 22 and IMC in 18 patients, but 9 patients (41%) with HGD progressed to invasive cancer during endotherapy. The median follow-up was 82 months. Four patients had an esophagectomy, and in the remaining 36 patients, 70 ERs and 111 ablations were performed. The median number of endoscopic sessions was 4 in patients with short segment compared with 7 in patients with long-segment Barrett's. Complete resolution of intestinal metaplasia (CRIM) was achieved in 30 patients (83%) at a median of 21 months. In 18 patients (60%), CRIM was maintained, whereas 12 patients developed recurrence at a median of 14 months. Additional endotherapy (n = 11) led to CRIM again in 10 patients (83%). There were no cancer deaths when CRIM was achieved. Overall survival with endotherapy was 73% at 5 years and 67% at 10 years. Quality of life (QOL) was below population means in 4 of 8 areas, but alimentary satisfaction was good after endotherapy. Endotherapy is successful in most patients, but multiple sessions are usually required and disease progression can occur. Once CRIM is achieved, recurrence is common and mandates continued endoscopic follow-up. QOL is impaired with endotherapy, but alimentary satisfaction and oncologic outcomes support esophageal preservation with endotherapy for patients with HGD or IMC.
Sections du résumé
OBJECTIVE
To review the workload, type and frequency of recurrence, long-term quality of life (QOL), and late oncologic outcomes with endoscopic therapy.
BACKGROUND
The short-term oncologic efficacy of endoscopic resection (ER) and ablation for patients with high-grade dysplasia (HGD) or intramucosal adenocarcinoma (IMC) is well-established in the literature.
METHODS
A retrospective chart review was performed of the initial 40 patients who had endoscopic therapy from 2001 to 2010 at 1 center by 1 physician.
RESULTS
Initial pathology was HGD in 22 and IMC in 18 patients, but 9 patients (41%) with HGD progressed to invasive cancer during endotherapy. The median follow-up was 82 months. Four patients had an esophagectomy, and in the remaining 36 patients, 70 ERs and 111 ablations were performed. The median number of endoscopic sessions was 4 in patients with short segment compared with 7 in patients with long-segment Barrett's. Complete resolution of intestinal metaplasia (CRIM) was achieved in 30 patients (83%) at a median of 21 months. In 18 patients (60%), CRIM was maintained, whereas 12 patients developed recurrence at a median of 14 months. Additional endotherapy (n = 11) led to CRIM again in 10 patients (83%). There were no cancer deaths when CRIM was achieved. Overall survival with endotherapy was 73% at 5 years and 67% at 10 years. Quality of life (QOL) was below population means in 4 of 8 areas, but alimentary satisfaction was good after endotherapy.
CONCLUSIONS
Endotherapy is successful in most patients, but multiple sessions are usually required and disease progression can occur. Once CRIM is achieved, recurrence is common and mandates continued endoscopic follow-up. QOL is impaired with endotherapy, but alimentary satisfaction and oncologic outcomes support esophageal preservation with endotherapy for patients with HGD or IMC.
Identifiants
pubmed: 30247330
doi: 10.1097/SLA.0000000000003038
pii: 00000658-202004000-00018
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
701-708Références
Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57:1200–1206.
Zehetner J, DeMeester SR, Hagen JA, et al. Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg 2011; 141:39–47.
Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal quality of life index: development, validation and application of a new instrument. Br J Surg 1995; 82:216–222.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473–483.
Greene CL, DeMeester SR, Worrell SG, et al. Alimentary satisfaction, gastrointestinal symptoms, and quality of life 10 or more years after esophagectomy with gastric pull-up. J Thorac Cardiovasc Surg 2014; 147:909–914.
Schembre DB, Huang JL, Lin OS, et al. Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy. Gastrointest Endosc 2008; 67:595–601.
Ferguson MK, Naunheim KS. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg 1997; 114:824–829.
Peyre CG, DeMeester SR, Rizzetto C, et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 2007; 246:665–671. discussion 671–664.
Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254:67–72.
Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146:652–660. e651.
Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137:815–823.
Fovos A, Jarral O, Panagiotopoulos N, et al. Does endoscopic treatment for early oesophageal cancers give equivalent oncological outcomes as compared with oesophagectomy? Best evidence topic (BET). Int J Surg 2012; 10:415–420.
Pohl H, Sonnenberg A, Strobel S, et al. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis. Gastrointest Endosc 2009; 70:623–631.
Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011; 253:271–278.
Sepesi B, Watson TJ, Zhou D, et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg 2010; 210:418–427.
Mohiuddin K, Dorer R, El Lakis MA, et al. Outcomes of surgical resection of T1bN0 esophageal cancer and assessment of endoscopic mucosal resection for identifying low-risk cancers appropriate for endoscopic therapy. Ann Surg Oncol 2016; 23:2673–2678.
Dubecz A, Kern M, Solymosi N, et al. Predictors of lymph node metastasis in surgically resected T1 esophageal cancer. Ann Thorac Surg 2015; 99:1879–1885. [discussion 1886].
Worrell SG, Boys JA, Chandrasoma P, et al. Inter-observer variability in the interpretation of endoscopic mucosal resection specimens of esophageal adenocarcinoma: interpretation of ER specimens. J Gastrointest Surg 2016; 20:140–144. [discussion 144–145].
Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol 2008; 15:3278–3288.
Boys JA, Worrell SG, Chandrasoma P, et al. Can the risk of lymph node metastases be gauged in endoscopically resected submucosal esophageal adenocarcinomas? A multi-center study. J Gastrointest Surg 2016; 20:6–12. [discussion 12].
Manner H, Pech O, Heldmann Y, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013; 11:630–635. [quiz e645].
Knabe M, May A, Ell C. Endoscopic therapy of early carcinoma of the oesophagus. Viszeralmedizin 2015; 31:320–325.
Schwameis K, Green KM, Worrell SG, et al. Outcome with primary en-bloc esophagectomy for submucosal esophageal adenocarcinoma. Ann Surg Oncol 2017; 24:3921–3925.
Molena D, Schlottmann F, Boys JA, et al. Esophagectomy following endoscopic resection of submucosal esophageal cancer: a highly curative procedure even with nodal metastases. J Gastrointest Surg 2017; 21:62–67.
Cotton CC, Wolf WA, Overholt BF, et al. Late recurrence of Barrett's esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in Intestinal Metaplasia Containing Dysplasia Trial. Gastroenterology 2017; 153:681–688. e682.
Herrero LA, van Vilsteren FG, Visser M, et al. Simultaneous use of endoscopic resection and radiofrequency ablation is not safe in an esophageal porcine model. Dis Esophagus 2015; 28:25–31.
Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118:670–677.
Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65:3–10.
Guarner-Argente C, Buoncristiano T, Furth EE, et al. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc 2013; 77:190–199.
Anders M, Bahr C, El-Masry MA, et al. Long-term recurrence of neoplasia and Barrett's epithelium after complete endoscopic resection. Gut 2014; 63:1535–1543.
Belghazi K, van Vilsteren FGI, Weusten B, et al. Long-term follow-up results of stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia. Gastrointest Endosc 2018; 87:77–84.
Greene CL, Worrell SG, Attwood SE, et al. Emerging concepts for the endoscopic management of superficial esophageal adenocarcinoma. J Gastrointest Surg 2016; 20:851–860.
Maret-Ouda J, Konings P, Lagergren J, et al. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg 2016; 263:251–257.
Johnson CS, Louie BE, Wille A, et al. The durability of endoscopic therapy for treatment of Barrett's metaplasia, dysplasia, and mucosal cancer after nissen fundoplication. J Gastrointest Surg 2015; 19:799–805.
Zhang Y, Yang X, Geng D, et al. The change of health-related quality of life after minimally invasive esophagectomy for esophageal cancer: a meta-analysis. World J Surg Oncol 2018; 16:97.
Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol 2012; 30:413–418.
Mantoan S, Cavallin F, Pinto E, et al. Long-term quality of life after esophagectomy with gastric pull-up. J Surg Oncol 2018; 117:970–976.
Rosmolen WD, Nieuwkerk PT, Pouw RE, et al. Quality of life and fear of cancer recurrence after endoscopic treatment for early Barrett's neoplasia: a prospective study. Dis Esophagus 2017; 30:1–9.